GSK plc (GSK) Form 6-K — Oct 28, 2026
GSK plc reported Q3 2026 turnover of £8,887 million, up 5% at constant exchange rates, led by Specialty Medicines (+15% CER) with strong HIV, RI&I and Oncology growth, while Vaccines declined 2% in the quarter on weaker Shingrix and Arexvy sales. Core EPS was 54.6p (+1% CER), but Total EPS fell 23% to 38.5p, driven by £328 million of Accelerate Growth restructuring charges, a £920 million Shionogi contingent consideration remeasurement, and prior impairments including £1,334 million for camlipixant. GSK reaffirmed full-year 2026 guidance: turnover up 3-5% (upper half), Core operating profit up 7-9% (upper half), and Core EPS up 7-9% (lower half), and declared a Q3 dividend of 17p per share.
Key figures
- Eps
- 54.6p Core / 38.5p Total in Q3 2026
- Revenue
- 8887000000
- Guidance
- FY2026 at CER: turnover +3-5% (upper half), Core operating profit +7-9% (upper half), Core EPS +7-9% (lower half); royalty income ~£900m; net interest charges ~£700-750m; tax rate ~17.5%
- Net Income
- £1,543m profit attributable to shareholders in Q3 2026
- Total Debt
- 23701000000
- Revenue Yoy
- 5% CER / 4% AER in Q3 2026; £24,925m YTD
- Cash Position
- 2962000000
- Shares Outstanding
- 4,009 million shares in free issue at 30 September 2026
- Net debt
- £20,739m at 30 September 2026 vs £14,453m at 31 December 2025
- Q3 dividend
- 17p per share declared for Q3 2026
- Rapt acquisition
- US$2.3bn (£1.7bn), completed 3 March 2026
- Buyback completed
- £2bn programme completed 26 June 2026 (124m shares, £2,011m)
- Alector termination
- £371 million
- Total eps q3 change
- -21% CER / -23% AER
- Free cash inflow ytd
- £4,887m
- Nuvalent acquisition
- US$10.8bn (£8.0bn) equity value, completed 15 July 2026
- Camlipixant impairment
- £1,334 million
- Contingent consideration
- £6,629m at 30 September 2026
- Core operating profit q3
- £3,076m (+5% CER)
- Accelerate growth restructuring q3
- £328 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.